These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18410881)

  • 1. Public health approach to addressing hyperphosphatemia among dialysis patients.
    Sehgal AR; Sullivan C; Leon JB; Bialostosky K
    J Ren Nutr; 2008 May; 18(3):256-61. PubMed ID: 18410881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks.
    Brauer A; Waheed S; Singh T; Maursetter L
    J Ren Nutr; 2019 Mar; 29(2):156-162. PubMed ID: 30087012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How KDIGO will (or will not) influence the management of hyperphosphatemia.
    Kovesdy CP
    Semin Dial; 2011; 24(1):35-6. PubMed ID: 21338391
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperphosphatemia in renal failure.
    Robb M
    RN; 2008 Dec; 71(12):26-30; quiz 31. PubMed ID: 19108567
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial.
    Sullivan C; Sayre SS; Leon JB; Machekano R; Love TE; Porter D; Marbury M; Sehgal AR
    JAMA; 2009 Feb; 301(6):629-35. PubMed ID: 19211470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using concordance with dosing techniques to achieve phosphate control.
    Koester LA; Rothstein M
    Nephrol News Issues; 2013 Nov; 27(12):22, 24, 26-8 passim. PubMed ID: 24354233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are calcium-based phosphate binders ever preferable in dialysis patients?
    Jain N; Reilly RF
    Semin Dial; 2014; 27(3):269-72. PubMed ID: 24620781
    [No Abstract]   [Full Text] [Related]  

  • 8. The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series.
    Moroșan E; Popovici V; Elian V; Dărăban AM; Rusu AI; Licu M; Mititelu M; Karampelas O
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional benefit of dietitian involvement in dialysis staffs-led diet education on uncontrolled hyperphosphatemia in hemodialysis patients.
    Tsai WC; Yang JY; Luan CC; Wang YJ; Lai YC; Liu LC; Peng YS
    Clin Exp Nephrol; 2016 Oct; 20(5):815-821. PubMed ID: 26658792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis.
    Hamano T; Fukagawa M
    Kidney Int; 2024 Aug; 106(2):191-195. PubMed ID: 39032965
    [No Abstract]   [Full Text] [Related]  

  • 12. Sevelamer.
    Wrong O; Harland C
    Nephrol Dial Transplant; 2008 Jun; 23(6):2108; author reply 2101-2. PubMed ID: 18400812
    [No Abstract]   [Full Text] [Related]  

  • 13. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
    Chan MW; Cheah HM; Mohd Padzil MB
    Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dealing with phosphorus: a patient perspective.
    King CN
    Nephrol News Issues; 2013 Aug; 27(9):27-8. PubMed ID: 24133842
    [No Abstract]   [Full Text] [Related]  

  • 15. EPIC Trial: education programme impact on serum phosphorous control in CKD 5D patients on hemodialysis.
    Martins CTB; Biavo BMM; Uezima CBB; Santos JAPD; Barros CM; Ribeiro Júnior E; Troconis PC; Scavone C; Luiz MVSJ
    J Bras Nefrol; 2017; 39(4):398-405. PubMed ID: 29319766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life.
    Gardulf A; Pålsson M; Nicolay U;
    Clin Nephrol; 2011 Apr; 75(4):319-27. PubMed ID: 21426886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of nicotinamide to treat hyperphosphatemia in dialysis patients.
    Lenglet A; Liabeuf S; Guffroy P; Fournier A; Brazier M; Massy ZA
    Drugs R D; 2013 Sep; 13(3):165-73. PubMed ID: 24000048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial.
    Akizawa T; Tsuruta Y; Okada Y; Miyauchi Y; Suda A; Kasahara H; Sasaki N; Maeda Y; Suzuki T; Matsui N; Niwayama J; Suzuki T; Hara H; Asano Y; Komemushi S; Fukagawa M
    BMC Nephrol; 2014 Jun; 15():98. PubMed ID: 24968790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When is Vitamin D contraindicated in dialysis patients?
    Lewin E; Olgaard K
    Semin Dial; 2009; 22(3):240-2. PubMed ID: 19572998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.